title: Eribulin mesylate.
authors.forename: Timothy K
authors.initials: TK
authors.lastname: Huyck
authors.forename: William
authors.initials: W
authors.lastname: Gradishar
authors.forename: Fil
authors.initials: F
authors.lastname: Manuguid
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D004988:Ethers, Cyclic / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D005663:Furans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018942:Macrolides; D008698:Mesylates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008870:Microtubules / Q000187:drug effects; D009362:Neoplasm Metastasis; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D004988:Ethers, Cyclic; D005663:Furans; D007659:Ketones; D018942:Macrolides; D008698:Mesylates; C070519:halichondrin B; D000095662:Polyether Polyketides; C490954:eribulin